Is Sanofi Undervalue by 22% ?

20 nov 2023

I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects on pharmaceutical companies, I believe Sanofi presents a compelling opportunity to purchase its stock with potentially lower risk.
I would be glad to share my detailed analysis for any one interested in more in debt explorations

Disclaimer:
This information is based on my personal analysis and is not to be considered financial advice. I am expressing my own views and opinions on the current market conditions and Sanofi's stock. Always conduct your own research and consider seeking advice from a qualified financial professional before making any investment decisions.